Zotarolimus
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Enzyme inhibitors |
| Catalog number | BBF-04052 |
| CAS | 221877-54-9 |
| Molecular Weight | 966.21 |
| Molecular Formula | C52H79N5O12 |
| Purity | >98% |
Online Inquiry
Description
Zotarolimus (INN, codenamed ABT-578) is an immunosuppressant. It is a semi-synthetic derivative of rapamycin. It was designed for use in stents with phosphorylcholine as a carrier. Coronary stents reduce early complications and improve late clinical outcomes in patients needing interventional cardiology.
Specification
| Synonyms | A-179578; A 179578; A179578; ABT-578; ABT578; ABT 578 |
| Storage | Store at -20°C |
| IUPAC Name | (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-12-[(2R)-1-[(1S,3R,4S)-3-methoxy-4-(tetrazol-1-yl)cyclohexyl]propan-2-yl]-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone |
| Canonical SMILES | CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)N5C=NN=N5)C)C)O)OC)C)C)C)OC |
| InChI | InChI=1S/C52H79N5O12/c1-31-16-12-11-13-17-32(2)43(65-8)28-39-21-19-37(7)52(64,69-39)49(61)50(62)56-23-15-14-18-41(56)51(63)68-44(34(4)26-38-20-22-40(45(27-38)66-9)57-30-53-54-55-57)29-42(58)33(3)25-36(6)47(60)48(67-10)46(59)35(5)24-31/h11-13,16-17,25,30-31,33-35,37-41,43-45,47-48,60,64H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12-,32-17+,36-25+/t31-,33-,34-,35-,37-,38+,39+,40+,41+,43+,44+,45-,47-,48+,52-/m1/s1 |
| InChI Key | CGTADGCBEXYWNE-GTTQIJKGSA-N |
| Source | Streptomyces hygroscopicus |
Properties
| Appearance | White Solid |
| Boiling Point | 1016.2±75.0°C at 760 mmHg |
| Melting Point | 100-105°C |
| Density | 1.3±0.1 g/cm3 |
| Solubility | Soluble in ethanol, methanol, DMF, DMSO |
Reference Reading
1.Biodegradable polymer stents vs second generation drug eluting stents: A meta-analysis and systematic review of randomized controlled trials.
Pandya B1, Gaddam S1, Raza M1, Asti D1, Nalluri N1, Vazzana T1, Kandov R1, Lafferty J1. World J Cardiol. 2016 Feb 26;8(2):240-6. doi: 10.4330/wjc.v8.i2.240.
AIM: To evaluate the premise, that biodegradable polymer drug eluting stents (BD-DES) could improve clinical outcomes compared to second generation permanent polymer drug eluting stents (PP-DES), we pooled the data from all the available randomized control trials (RCT) comparing the clinical performance of both these stents.
2.Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial.
Crimi G1, Leonardi S1, Costa F2, Adamo M2, Ariotti S3, Valgimigli M4. Int J Cardiol. 2016 Mar 17;212:110-117. doi: 10.1016/j.ijcard.2016.03.033. [Epub ahead of print]
AIM: Chronic kidney disease (CKD) is a powerful predictor of major cardiovascular events and stent thrombosis (ST) in patients undergoing percutaneous coronary interventions (PCI). No randomized data are available to compare, and guide the selection of type of stent between bare metal (BMS) or drug eluting stent (DES) in this population.
3.Comparison on the efficacy of everolimus-eluting stent and zotarolimus-eluting stents in coronary heart disease between diabetic and non-diabetic patients.
Lin L1, Jin C2, Wei X2, Li H2, Shi J2, Wu S2, Yang X3, Qi X4. Int J Clin Exp Med. 2015 Nov 15;8(11):20813-20. eCollection 2015.
OBJECTIVE: The aim of this study is to examine and compare the efficacy of everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) in coronary heart disease in diabetic or non-diabetic patients.
Recommended Products
| BBF-00969 | Homomycin | Inquiry |
| BBF-03211 | AT-265 | Inquiry |
| BBF-03774 | Cephalosporin C Zinc Salt | Inquiry |
| BBF-03954 | Polymyxin B nonapeptide | Inquiry |
| BBF-03891 | Cefsulodin sodium | Inquiry |
| BBF-05806 | Zeaxanthin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
